Biolytica scoops $5.8 million to build out revolutionary AI-driven longevity platform
Swiss-based longevity startup Biolytica announced today that it has successfully secured funding totalling CHF 5.25m (US$5.8m) from the Max imon Longevity Co-Investment Fund. Biolytica’s focus is its Biolytica NEXUS health data platform, a revolutionary AI-driven analytics platform that aggregates, visualizes and analyzes a whole raft of data, including genomics, blood, microbiome and epigenetic biomarkers, wearable devices, lifestyle data and more.
Read More from the Global Wellness News ™